WO2009017161A1 - 炎症性サイトカインの抑制剤 - Google Patents
炎症性サイトカインの抑制剤 Download PDFInfo
- Publication number
- WO2009017161A1 WO2009017161A1 PCT/JP2008/063676 JP2008063676W WO2009017161A1 WO 2009017161 A1 WO2009017161 A1 WO 2009017161A1 JP 2008063676 W JP2008063676 W JP 2008063676W WO 2009017161 A1 WO2009017161 A1 WO 2009017161A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- production
- found
- inflammatory
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
ヒトCD36を強制発現させたヒト培養細胞293Tでマウスを免疫し、得られた抗体のサイトカイン産生制御効果について検討したところ、PBMCによるIFNγ産生を単独で強く抑制する抗CD36抗体を見出した。他のサイトカイン産生に対する効果についても検討したところ、上記抗CD36抗体は代表的な炎症性サイトカインの産生を確実に抑制することが明らかになった。さらに上記抗CD36抗体に抗炎症性サイトカイン産生促進能があることを確認した。本発明の抗体は、主要な炎症性サイトカインの産生を抑制することにより、または抗炎症性サイトカインの産生を促進することにより、炎症性疾患治療を可能にする。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007197773A JP2010235447A (ja) | 2007-07-30 | 2007-07-30 | 炎症性サイトカインの抑制剤 |
JP2007-197773 | 2007-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009017161A1 true WO2009017161A1 (ja) | 2009-02-05 |
Family
ID=40304391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/063676 WO2009017161A1 (ja) | 2007-07-30 | 2008-07-30 | 炎症性サイトカインの抑制剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2010235447A (ja) |
WO (1) | WO2009017161A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2572730A1 (en) * | 2010-05-20 | 2013-03-27 | Toru Miyazaki | Method for prevention or treatment of metabolic syndrome |
WO2013096380A3 (en) * | 2011-12-20 | 2013-08-22 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
US10766953B2 (en) | 2017-03-16 | 2020-09-08 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102404845B1 (ko) * | 2018-10-16 | 2022-06-07 | 가톨릭대학교 산학협력단 | 인간화된 자가면역 질환 동물 모델 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026403A1 (en) * | 1994-03-29 | 1995-10-05 | Celltech Therapeutics Limited | Antibodies against e-selectin |
WO2002022150A2 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes antithrombin iii |
WO2002032445A2 (de) * | 2000-10-20 | 2002-04-25 | Beate Kehrel | Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus |
WO2004068931A2 (en) * | 2003-02-07 | 2004-08-19 | Protein Design Labs Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
WO2006113909A2 (en) * | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
-
2007
- 2007-07-30 JP JP2007197773A patent/JP2010235447A/ja active Pending
-
2008
- 2008-07-30 WO PCT/JP2008/063676 patent/WO2009017161A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026403A1 (en) * | 1994-03-29 | 1995-10-05 | Celltech Therapeutics Limited | Antibodies against e-selectin |
WO2002022150A2 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes antithrombin iii |
WO2002032445A2 (de) * | 2000-10-20 | 2002-04-25 | Beate Kehrel | Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus |
WO2004068931A2 (en) * | 2003-02-07 | 2004-08-19 | Protein Design Labs Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
WO2006113909A2 (en) * | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
Non-Patent Citations (5)
Title |
---|
DOYEN V. ET AL.: "Thrombospondin 1 Is an Autocrine Negative Regulator of Human Dendritic Cell Activation", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 8, 2003, pages 1277 - 1283, XP002403013 * |
IKEDA Y. ET AL.: "Aggregated Ursolic Acid, a Natural Triterpenoid, Induces IL-1beta Release from Murine Peritoneal Macrophages: Role of CD36", THE JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, 15 April 2007 (2007-04-15), pages 4854 - 4864 * |
MASLI S. ET AL.: "Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells", INTERNATIONAL IMMUNOLOGY, vol. 18, no. 5, 2006, pages 689 - 699 * |
URBAN B.C. ET AL.: "A role for CD36 in the regulation of dendritic cell function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 15, 2001, pages 8750 - 8755 * |
YEHUALASHET T. ET AL.: "A CD36 Synthetic Peptide Inhibits Bleomycin-Induced Pulmonary Inflammation and Connective Tissue Synthesis in the Rat", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 23, no. 2, 2000, pages 204 - 212 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2572730A1 (en) * | 2010-05-20 | 2013-03-27 | Toru Miyazaki | Method for prevention or treatment of metabolic syndrome |
EP2572730A4 (en) * | 2010-05-20 | 2013-11-06 | Toru Miyazaki | PROCESS FOR PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME |
CN103648531A (zh) * | 2010-05-20 | 2014-03-19 | 宫崎彻 | 用于预防或治疗代谢综合症的方法 |
WO2013096380A3 (en) * | 2011-12-20 | 2013-08-22 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
US9371376B2 (en) | 2011-12-20 | 2016-06-21 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
US9745371B2 (en) | 2011-12-20 | 2017-08-29 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
EA027975B1 (ru) * | 2011-12-20 | 2017-09-29 | Янссен Байотек, Инк. | Анти-псф-тау-антитела и их применение |
US10000559B2 (en) | 2011-12-20 | 2018-06-19 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
US10196440B2 (en) | 2011-12-20 | 2019-02-05 | Janssen Biotech, Inc. | Anti-PHG-tau antibodies and their uses |
US10766953B2 (en) | 2017-03-16 | 2020-09-08 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and uses thereof |
US11365244B2 (en) | 2017-03-16 | 2022-06-21 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2010235447A (ja) | 2010-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30931A1 (es) | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso | |
MX2011010908A (es) | Anticuerpos anti-tnf-alfa y sus usos. | |
PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
WO2007126439A3 (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
WO2010068794A3 (en) | Hif inhibitors and use thereof | |
WO2010070675A3 (en) | Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof | |
HN2011002037A (es) | Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido | |
SG10201803862UA (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
MX2015002289A (es) | Anticuerpos humanos para gfr alfa 3 y métodos para su uso. | |
UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
DOP2016000006A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
CO6150099A2 (es) | Agente de mejoramiento de fermentacion del rumen | |
NZ594365A (en) | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders | |
UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
NZ578065A (en) | Methods for treating psoriasis with an antibody which binds to an epitope | |
UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
ATE520032T1 (de) | Differentielle cytokinexpression bei einer menschlichen krebserkrankung | |
WO2006090388A3 (en) | Fruit cell culture extract for treating inflammation | |
WO2009017161A1 (ja) | 炎症性サイトカインの抑制剤 | |
PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
DE602007005041D1 (de) | Verfahren zur Behandlung von Entzündungserkrankungen mit Maracujaextrakten | |
WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth | |
MX2011011559A (es) | Parasiticidas sanguineos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08791907 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08791907 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |